Why patients fail to seek information on OTC product interactions with a direct-acting oral anticoagulant: perspectives on information-seeking
Patients taking apixaban raised reasons for not seeking information about potential OTC product interactions that included poor awareness, perceptions regarding the safety of OTC products, and beliefs in provider responsibility for informing them about interactions. Greater patient education is needed regarding the potential for OTC product-DOAC interactions and the regulation of OTC products, particularly dietary supplements.
Authors
- Janice B. Schwartz (ORCID: https://orcid.org/0000-0002-5171-7824)
- Marley P.D. Magee (ORCID: https://orcid.org/0009-0005-4983-4545)
- Ruey‐Ying Liu (ORCID: https://orcid.org/0000-0002-2770-2147)
- Derjung M. Tarn (ORCID: https://orcid.org/0000-0001-7426-6387)
- Amanda McArthur (ORCID: https://orcid.org/0000-0002-0912-8006)
Institutions
- Johns Hopkins University (US)
- University of California, Los Angeles (US)
- University of California, San Francisco (US)
- Johns Hopkins Medicine (US)
- National Chengchi University (TW)
Publication Details
- Journal
- BMC Primary Care
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1186/s12875-025-02740-1
- Citations
- 1
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Bristol-Myers Squibb
- Pfizer
- National Institutes of Health
- University of California, San Francisco
- National Center for Advancing Translational Sciences
- Clinical and Translational Science Institute, University of California, Los Angeles